# Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

> **NCT05375435** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Dermatomyositis, Adult Type
- Interstitial Lung Disease

## Interventions

- **DRUG:** triple therapy
- **DRUG:** dual-therapy

## Key facts

- **NCT ID:** NCT05375435
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375435, "Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05375435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*